Marinomed Biotech AG Evaluates 10% Capital Increase

Marinomed Biotech AG announced today that its Management Board is evaluating a possible capital increase. The proposal includes issuing up to 154,053 new shares, representing 10% of the existing share capital. This comes with the exclusion of statutory subscription rights for existing shareholders.

The aim is to finance ongoing costs in the restructuring proceedings, cover part of the restructuring plan, and support continuing operations. Discussions with selected investors are planned to assess the potential transaction.

Implementation depends on these discussions, further resolutions by the Management Board, and approvals from the Supervisory Board and the restructuring administrator, which are still pending.

If carried out, the Management Board is also considering a possible second capital increase under similar terms.